<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00340678</url>
  </required_header>
  <id_info>
    <org_study_id>999995037</org_study_id>
    <secondary_id>OH95-DK-N037</secondary_id>
    <nct_id>NCT00340678</nct_id>
  </id_info>
  <brief_title>Renoprotection in Early Diabetic Nephropathy in Pima Indians</brief_title>
  <official_title>Renoprotection in Early Diabetic Nephropathy in Pima Indians</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation is a randomized, double-blinded, placebo-controlled clinical trial in
      adult diabetic Pima Indians with normal urinary albumin excretion (albumin-to-creatinine
      ration less than 30 mg/g) or microalbuminuria (albumin-to-creatinine ration = 30-299 mg/g) to
      test the hypothesis that blockade of the renin-angiotensin system with the angiotensin
      receptor blocker (ARB) losartan can prevent or further attenuate the development and
      progression of early diabetic nephropathy in subjects with type 2 diabetes mellitus who are
      receiving standard diabetes care.

      One hundred seventy subjects were recruited for the study, all of whom had type 2 diabetes
      for at least 5 years, serum creatinine concentrations less than 1.4 mg/dl, and no evidence of
      non-diabetic renal diseases. Ninety-two of the subjects had normal urinary albumin excretion
      at baseline and other 78 had microalbuminuria. Subjects in each albumin excretion group were
      randomized to treatment with either the angiotensin II receptor antagonist, losartan, or
      placebo. Measurements of glomerular filtration rate (GFR), renal plasma flow (RPF) and
      fractional clearances of albumin and IgG will be made initially, at one month, and at
      12-month intervals from baseline thereafter. A kidney biopsy was performed after six years in
      111 subjects. Morphometric analysis of renal biopsies was used to determine differences in
      glomerular structure between treatment groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigation is a randomized, double-blinded, placebo-controlled clinical trial in
      adult diabetic Pima Indians with normal urinary albumin excretion (albumin-to-creatinine
      ratio &lt; 30 mg/g) or microalbuminuria (albumin-to-creatinine ratio = 30-299 mg/g) to test the
      hypothesis that blockade of the renin-angiotensin system with the angiotensin receptor
      blocker (ARB) losartan can prevent or further attenuate the development and progression of
      early diabetic nephropathy in subjects with type 2 diabetes mellitus who are receiving
      standard diabetes care.

      One hundred seventy subjects were recruited for the study, all of whom had type 2 diabetes
      for at least 5 years, serum creatinine concentrations &lt; 1.4 mg/dl, and no evidence of
      non-diabetic renal diseases. Ninety-two of the subjects had normal urinary albumin excretion
      at baseline and the other 78 had microalbuminuria. Subjects in each albumin excretion group
      were randomized to treatment with either the angiotensin II receptor antagonist, losartan, or
      placebo. Measurements of glomerular filtration rate (GFR), renal plasma flow (RPF) and
      fractional clearances of albumin and immunoglobulin G (IgG) were made initially, at one
      month, and at 12-month intervals from baseline thereafter. A kidney biopsy was be performed
      after six years in 111 subjects. Morphometric analysis of renal biopsies was used to
      determine differences in glomerular structure between treatment groups.

      The major outcome measure was a decline in GFR to less than or equal to 60 ml/min or to half
      the baseline value in subjects that enter the study with a GFR of &lt; 120 ml/min. Other
      measures of renoprotection were assessed, including group differences in 1) change in albumin
      excretion, 2) change in serum creatinine concentration, and 3) glomerular morphology in all
      subjects as outlined above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Decline in GFR</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Volume</measure>
    <time_frame>6 years after first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Normoalbuminuria Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoalbuminuria Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microalbuminuria Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microalbuminuria Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
    <arm_group_label>Normoalbuminuria Losartan</arm_group_label>
    <arm_group_label>Microalbuminuria Losartan</arm_group_label>
    <other_name>Cozaar</other_name>
    <other_name>MK-954</other_name>
    <other_name>DuP 753</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment with placebo corresponding to each dose of losartan.</description>
    <arm_group_label>Normoalbuminuria Placebo</arm_group_label>
    <arm_group_label>Microalbuminuria Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Volunteers from the Gila River Indian Community who meet the eligibility criteria will be
        invited to participate.

        To be eligible for participation in the study, subjects must meet the following criteria:

          -  Aged 18-65.

          -  Diagnosis of type 2 diabetes greater than or equal to 5 years.

          -  Serum creatinine concentration less than to 1.4 mg/dl.

          -  Serum potassium concentration less than or equal to 5.5 milliequivalents (mEq)/L.

          -  At least 2 of 3 weekly screening urinary albumin-to-creatinine ratios less than 300
             mg/g. All screening tests are to be within 3 months of enrollment.

          -  Willingness, after receiving a thorough explanation of the study, to participate.

        EXCLUSION CRITERIA:

        Subjects will be excluded for the following reasons:

          -  Clinically significant disorders of the liver, cardiovascular disease, cerebrovascular
             disease, peripheral vascular disease, pulmonary diseases, renal-urinary disorders,
             gastrointestinal disorders, or hematocrit levels less than or equal to 30 percent in
             women or less than or equal to 35 percent in men.

          -  Renovascular or malignant hypertension; uncontrolled hypertension despite treatment
             with three antihypertensive drugs; or hypertension that is being treated with
             antihypertensive medicines and the primary care physician or the patient refuses to
             adopt the blood pressure treatment regimen outlined in the study protocol.

          -  Hematuria of unknown etiology.

          -  Chronic debilitating disorders with or without treatment that would interfere with the
             assessment of kidney function or that might reduce the chances of survival for a
             sufficient length of time to evaluate efficacy of treatment.

          -  Currently receiving a drug regimen that includes: steroids, immunosuppressants, or
             investigational new drugs.

          -  Pregnancy. Women of childbearing potential must have a negative pregnancy test prior
             to entry and every three months during the study.

          -  Evidence of inability to empty the bladder.

          -  Hypersensitivity to angiotensin-converting enzyme inhibitors (ACEi), ARBs, or iodine.

          -  Bleeding disorders, since kidney biopsies could not be performed safely in these
             individuals.

          -  Massive obesity with body mass index greater than or equal to 45 kg/m(2).

          -  Non-diabetic renal disease.

          -  Conditions that are likely to interfere with informed consent or compliance with the
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Nelson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIDDK, Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5963-7.</citation>
    <PMID>3862110</PMID>
  </reference>
  <reference>
    <citation>Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986 Jun;77(6):1925-30.</citation>
    <PMID>3011862</PMID>
  </reference>
  <reference>
    <citation>Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989 Oct;36(4):526-36.</citation>
    <PMID>2681929</PMID>
  </reference>
  <results_reference>
    <citation>Weil EJ, Fufaa G, Jones LI, Lovato T, Lemley KV, Hanson RL, Knowler WC, Bennett PH, Yee B, Myers BD, Nelson RG. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013 Sep;62(9):3224-31. doi: 10.2337/db12-1512. Epub 2013 Apr 1. Erratum in: Diabetes. 2018 Jan 5;:.</citation>
    <PMID>23545707</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <results_first_submitted>March 26, 2013</results_first_submitted>
  <results_first_submitted_qc>October 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2013</results_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiotensin II Receptor Antagonist</keyword>
  <keyword>Therapeutic Trial</keyword>
  <keyword>Glomerular Filtration Rate</keyword>
  <keyword>Kidney Biopsy</keyword>
  <keyword>Non-Insulin Dependent Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled between 1996 and 2001, the last biopsy was performed in 2007, and morphometric evaluation was completed in 2012.</recruitment_details>
      <pre_assignment_details>Of 313 patients with type 2 diabetes who were screened, 79 were ineligible, 50 declined to participate, and 14 had other reasons that prevented participation despite meeting eligibility requirements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normoalbuminuria Losartan</title>
          <description>Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
        </group>
        <group group_id="P2">
          <title>Normoalbuminuria Placebo</title>
          <description>Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.</description>
        </group>
        <group group_id="P3">
          <title>Microalbuminuria Losartan</title>
          <description>Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
        </group>
        <group group_id="P4">
          <title>Microalbuminuria Placebo</title>
          <description>Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of 170 subjects enrolled, one lost follow up. So all analysis was performed based on 169 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Normoalbuminuria Losartan</title>
          <description>Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
        </group>
        <group group_id="B2">
          <title>Normoalbuminuria Placebo</title>
          <description>Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.</description>
        </group>
        <group group_id="B3">
          <title>Microalbuminuria Losartan</title>
          <description>Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
        </group>
        <group group_id="B4">
          <title>Microalbuminuria Placebo</title>
          <description>Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="10.6"/>
                    <measurement group_id="B2" value="41.9" spread="11.7"/>
                    <measurement group_id="B3" value="41.8" spread="8.9"/>
                    <measurement group_id="B4" value="42.3" spread="10.9"/>
                    <measurement group_id="B5" value="41.3" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="4.7"/>
                    <measurement group_id="B2" value="10.4" spread="6.0"/>
                    <measurement group_id="B3" value="10.3" spread="5.2"/>
                    <measurement group_id="B4" value="14.1" spread="8.4"/>
                    <measurement group_id="B5" value="10.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index obtained by measuring the participant's height in meters and weight in kilograms.</description>
          <units>kg/(m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="8.8"/>
                    <measurement group_id="B2" value="36.6" spread="8.0"/>
                    <measurement group_id="B3" value="34.6" spread="9.1"/>
                    <measurement group_id="B4" value="33.8" spread="7.2"/>
                    <measurement group_id="B5" value="35.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure, systolic</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115" spread="11"/>
                    <measurement group_id="B2" value="118" spread="14"/>
                    <measurement group_id="B3" value="118" spread="15"/>
                    <measurement group_id="B4" value="123" spread="13"/>
                    <measurement group_id="B5" value="118" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure, diastolic</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="7"/>
                    <measurement group_id="B2" value="75" spread="7"/>
                    <measurement group_id="B3" value="77" spread="9"/>
                    <measurement group_id="B4" value="77" spread="7"/>
                    <measurement group_id="B5" value="76" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure, mean</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88" spread="7"/>
                    <measurement group_id="B2" value="89" spread="9"/>
                    <measurement group_id="B3" value="90" spread="10"/>
                    <measurement group_id="B4" value="92" spread="8"/>
                    <measurement group_id="B5" value="90" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>Glycosylated hemoglobin is an integrated measure of glycemic control that reflects an average glycemic level over the past 3 months.</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" spread="2.0"/>
                    <measurement group_id="B2" value="8.1" spread="2.2"/>
                    <measurement group_id="B3" value="9.5" spread="2.3"/>
                    <measurement group_id="B4" value="10.3" spread="2.1"/>
                    <measurement group_id="B5" value="9.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular filtration rate (GFR)</title>
          <description>Glomerular filtration rate was measured by the urinary clearance of iothalamate.</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171" spread="38"/>
                    <measurement group_id="B2" value="152" spread="40"/>
                    <measurement group_id="B3" value="166" spread="43"/>
                    <measurement group_id="B4" value="168" spread="43"/>
                    <measurement group_id="B5" value="164" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary albumin to creatinine ratio</title>
          <units>mg/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="B2" value="14" lower_limit="9" upper_limit="26"/>
                    <measurement group_id="B3" value="66" lower_limit="39" upper_limit="205"/>
                    <measurement group_id="B4" value="80" lower_limit="46" upper_limit="165"/>
                    <measurement group_id="B5" value="47" lower_limit="9" upper_limit="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Decline in GFR</title>
        <description>Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation.</description>
        <time_frame>Up to 6 years</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Normoalbuminuria Losartan</title>
            <description>Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
          </group>
          <group group_id="O2">
            <title>Normoalbuminuria Placebo</title>
            <description>Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.</description>
          </group>
          <group group_id="O3">
            <title>Microalbuminuria Losartan</title>
            <description>Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
          </group>
          <group group_id="O4">
            <title>Microalbuminuria Placebo</title>
            <description>Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decline in GFR</title>
          <description>Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation.</description>
          <population>Intention-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Volume</title>
        <time_frame>6 years after first treatment</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Normoalbuminuria Losartan</title>
            <description>Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
          </group>
          <group group_id="O2">
            <title>Normoalbuminuria Placebo</title>
            <description>Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.</description>
          </group>
          <group group_id="O3">
            <title>Microalbuminuria Losartan</title>
            <description>Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.</description>
          </group>
          <group group_id="O4">
            <title>Microalbuminuria Placebo</title>
            <description>Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Volume</title>
          <population>Intention-to-treat</population>
          <units>*10^6 cubic microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.8"/>
                    <measurement group_id="O2" value="5.6" spread="1.1"/>
                    <measurement group_id="O3" value="6.4" spread="2.3"/>
                    <measurement group_id="O4" value="7.0" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>Subjects received losartan</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects received placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Death from coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Death from leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death from bleeding gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death from multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Death from hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Death from alcoholic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Death from automobile accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral obstruction after kidney biopsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Renoprotection in Early Diabetic Nephropathy in Pima Indians</name_or_title>
      <organization>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</organization>
      <phone>(602) 200-5205</phone>
      <email>rnelson@phx.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

